Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 47

Sort by

Sort Order Select

Journal Articles

Emapalumab therapy for hemophagocytic lymphohistiocytosis prior to reduced-intensity transplantation improves chimerism

Bethany Verkamp, Sonata Jodele, Anthony Sabulski, Rebecca A Marsh, Pearce Kieser, Michael B. Jordan

Blood blood.2024025977.

https://doi.org/10.1182/blood.2024025977

Published: 2024

Includes: Supplemental data

Journal Articles

Diagnostic Guidelines for Familial Hemophagocytic Lymphohistiocytosis Revisited

Jan-Inge Henter, Elena Sieni, Julia Eriksson, Elisabet Bergsten, Ida Hed Myrberg, Scott Canna, Maria Luisa Coniglio, Randy Q Cron, Kate F Kernan, Ashish R. Kumar, Kai Lehmberg, Francesca Minoia, Ahmed Naqvi, Angelo Ravelli, Yongmin Tang, Matteo Bottai, Yenan T Bryceson, AnnaCarin Horne, Michael B. Jordan

Blood blood.2024025077.

https://doi.org/10.1182/blood.2024025077

Published: 2024

Includes: Supplemental data

Journal Articles

Real-World Treatment Patterns and Outcomes Among Patients with Secondary Hemophagocytic Lymphohistiocytosis Treated with Emapalumab in the United States: The Real-HLH Study

Carl E Allen, Shanmuganathan Chandrakasan, Michael B. Jordan, Jennifer W Leiding, Abiola Oladapo, Priti Pednekar, Kelly Walkovich, John Yee

Blood (2023) 142 (Supplement 1): 3909.

https://doi.org/10.1182/blood-2023-186948

Published: 2023

Journal Articles

Treatments and Outcomes of Lymphoma-Associated Hyperinflammation- a Report from the HLH in Adults Working Group for the Histiocyte Society

Blood (2023) 142 (Supplement 1): 2537.

https://doi.org/10.1182/blood-2023-188829

Published: 2023

Journal Articles

Deep Proteomic Analysis Reveals Shared Terminal Mechanisms for Familial Hemophagocytic Lymphohistiocytosis and Lymphoma-Associated Hyperinflammation

Adi Zoref-Lorenz, Uri Abadi, Ronit Gurion, Alexander Osnis, Joanne Yacobovich, Yehudit Birger, Galit Berger Pinto, Pia Raanani, Arnon Nagler, Shai Dulberg, Asaf Madi, Gilad Itchaki, Martin H. Ellis, Shai Izraeli, Michael B. Jordan

Blood (2023) 142 (Supplement 1): 677.

https://doi.org/10.1182/blood-2023-189849

Published: 2023

Journal Articles

Compassionate Use of Emapalumab in Children with Life-Threatening Disorders: Real-World Data

Joanne Yacobovich, Jerry Stein, Michael B. Jordan, Oded Gilad, Dafna Brik Simon, Ofer Schiller, Eran Shostak, Orna Steinberg-Shemer, Aviva C. Krauss

Blood (2023) 142 (Supplement 1): 7335.

https://doi.org/10.1182/blood-2023-187398

Published: 2023

Journal Articles

Real-World Treatment Patterns and Outcomes Among Patients with Primary Hemophagocytic Lymphohistiocytosis with and without Infection at Diagnosis and Treated with Emapalumab: The Real-HLH Study

Carl E Allen, Shanmuganathan Chandrakasan, Michael B. Jordan, Jennifer W Leiding, Abiola Oladapo, Priti Pednekar, Kelly Walkovich, John Yee

Blood (2023) 142 (Supplement 1): 2534.

https://doi.org/10.1182/blood-2023-181777

Published: 2023

Journal Articles

Inflammatory Markers in Hemophagocytic Lymphohistiocytosis - a Single Centre Study

Caroline Spaner, Mariam Goubran, Sophie Stukas, Kamran Shojania, Amanda M Li, Mypinder Sekhon, Cheryl Wellington, Adi Zoref-Lorenz, Andre Mattman, Erica A. Peterson, Michael B. Jordan, Luke Y. C. Chen, Audi Setiadi

Blood (2023) 142 (Supplement 1): 5359.

https://doi.org/10.1182/blood-2023-178867

Published: 2023

Journal Articles

Emapalumab, a Fully Human Anti-Interferon Gamma Monoclonal Antibody, in Pediatric Patients with Primary Hemophagocytic Lymphohistiocytosis: Long-Term Follow-up of a Phase 2/3 Study

Michael B. Jordan, Carl Allen, Anupama Rao, Carmelo Rizzari, Simone Cesaro, Maria Caterina Putti, Julian Sevilla, Cristina de Min, Maria Ballabio, Veronica Asnaghi, Anna Stoltenberg, Radmila Kanceva, Franco Locatelli

Blood (2023) 142 (Supplement 1): 1174.

https://doi.org/10.1182/blood-2023-179362

Published: 2023

Journal Articles

Early Response Parameters during Etoposide-Based Hemophagocytic Lymphohistiocytosis Treatment in Children Predict Early Mortality

Joanne Yacobovich, Bethany Verkamp, Brenton J Francisco, Joana Marie Mack, Tucker Blackledge, Dafna Brik Simon, Adi Zoref-Lorenz, Michael B Jordan

Blood (2022) 140 (Supplement 1): 2612–2613.

https://doi.org/10.1182/blood-2022-167637

Published: 2022

Journal Articles

Deep Multi-Omic Analysis of Familial Hemophagocytic Lymphohistiocytosis Reveals Distinctive Immune Features of the Disease

Michael B Jordan, Adi Zoref-Lorenz, Pearce Charles Kieser, Galit Berger, Yehudit Birger, Shai Izraeli, Joanne Yacobovich

Blood (2022) 140 (Supplement 1): 2601–2602.

https://doi.org/10.1182/blood-2022-170799

Published: 2022

Journal Articles

Real-World Demographics, Clinical Characteristics, and Treatment Patterns of Patients Treated with Emapalumab for Primary Hemophagocytic Lymphohistiocytosis in the United States: The Real-HLH Study

Carl E. Allen, Shanmuganathan Chandrakasan, Michael B Jordan, Jennifer W Leiding, Abiola Oladapo, Priti Pednekar, Kelly J. Walkovich, John Yee

Blood (2022) 140 (Supplement 1): 2595–2596.

https://doi.org/10.1182/blood-2022-166649

Published: 2022

Journal Articles

The Optimized HLH Inflammatory Index Is Associated with a Higher Stage of Lymphoma, but an Unexpected High Mortality Associated with Inflammation

Blood (2022) 140 (Supplement 1): 8326–8328.

https://doi.org/10.1182/blood-2022-170790

Published: 2022

Journal Articles

Insights into the Natural History and Treatment Outcomes of Hemophagocytic Lymphohistiocytosis (HLH): The into-HLH Registry

Adi Zoref-Lorenz, David C. Fajgenbaum, Sheila K. Pierson, Abiola Oladapo, John Yee, Nitya Gulati, Carl E. Allen, Michael B. Jordan

Blood (2022) 140 (Supplement 1): 11170–11171.

https://doi.org/10.1182/blood-2022-170288

Published: 2022

Journal Articles

Quercetin ameliorates XIAP deficiency–associated hyperinflammation

Samuel C. C. Chiang, Erika Owsley, Neelam Panchal, Vijaya Chaturvedi, Catherine E. Terrell, Michael B. Jordan, Parinda A. Mehta, Stella M. Davies, Nagako Akeno, Claire Booth, Rebecca A. Marsh

Blood (2022) 140 (7): 706–715.

https://doi.org/10.1182/blood.2021014335

Published: 2022

Includes: Supplemental data

Journal Articles

HLH: birds of a feather flock together

Michael B. Jordan

Blood (2022) 140 (3): 167–168.

https://doi.org/10.1182/blood.2022016712

Published: 2022

Journal Articles

An improved index for diagnosis and mortality prediction in malignancy-associated hemophagocytic lymphohistiocytosis

Blood (2022) 139 (7): 1098–1110.

https://doi.org/10.1182/blood.2021012764

Published: 2022

Includes: Supplemental data

Journal Articles

Safety of Emapalumab in Pediatric Patients with Primary Hemophagocytic Lymphohistiocytosis (HLH): Relationship to Treatment Exposure

Michael B Jordan, Franco Locatelli, Philippe Jacqmin, Christian Laveille, Eric Snoeck, Cristina de Min

Blood (2021) 138 (Supplement 1): 2061.

https://doi.org/10.1182/blood-2021-150256

Published: 2021

Journal Articles

Real-World Treatment Patterns and Outcomes in Patients with Hemophagocytic Lymphohistiocytosis (HLH) and Other Clinical Conditions Treated with Emapalumab: The Real-HLH Study Design

Carl E. Allen, Jennifer Leiding, Shanmuganathan Chandrakasan, Kelly J. Walkovich, Abiola Oladapo, John Yee, Priti Pednekar, Sajjad Raza, Michael B Jordan

Blood (2021) 138 (Supplement 1): 4991.

https://doi.org/10.1182/blood-2021-148555

Published: 2021

Journal Articles

Peri-Transplant Alemtuzumab Levels Predict Risk of Secondary Graft Failure and Inversely Impact CXCL9 Levels after RIC HCT (A Correlative Biology Study to BMT-CTN 1204 RICHI)

Ashley V Geerlinks, Brooks Scull, Christa Krupski, Ryan Fleischmann, Michael A. Pulsipher, Mary Eapen, Jim A. Connelly, Catherine M. Bollard, Sung-Yun Pai, Christine N. Duncan, Leslie S Kean, K. Scott Baker, Lauri S Burroughs, Jeffrey R. Andolina, Michael B Jordan, Tsz-Kwong Man, Carl E. Allen, Rebecca A. Marsh

Blood (2021) 138 (Supplement 1): 748.

https://doi.org/10.1182/blood-2021-145629

Published: 2021

NARROW

Emapalumab therapy for hemophagocytic lymphohistiocytosis prior to reduced-intensity transplantation improves chimerism

Diagnostic Guidelines for Familial Hemophagocytic Lymphohistiocytosis Revisited

Real-World Treatment Patterns and Outcomes Among Patients with Secondary Hemophagocytic Lymphohistiocytosis Treated with Emapalumab in the United States: The Real-HLH Study

Treatments and Outcomes of Lymphoma-Associated Hyperinflammation- a Report from the HLH in Adults Working Group for the Histiocyte Society

Deep Proteomic Analysis Reveals Shared Terminal Mechanisms for Familial Hemophagocytic Lymphohistiocytosis and Lymphoma-Associated Hyperinflammation

Compassionate Use of Emapalumab in Children with Life-Threatening Disorders: Real-World Data

Real-World Treatment Patterns and Outcomes Among Patients with Primary Hemophagocytic Lymphohistiocytosis with and without Infection at Diagnosis and Treated with Emapalumab: The Real-HLH Study

Inflammatory Markers in Hemophagocytic Lymphohistiocytosis - a Single Centre Study

Emapalumab, a Fully Human Anti-Interferon Gamma Monoclonal Antibody, in Pediatric Patients with Primary Hemophagocytic Lymphohistiocytosis: Long-Term Follow-up of a Phase 2/3 Study

Early Response Parameters during Etoposide-Based Hemophagocytic Lymphohistiocytosis Treatment in Children Predict Early Mortality

Deep Multi-Omic Analysis of Familial Hemophagocytic Lymphohistiocytosis Reveals Distinctive Immune Features of the Disease

Real-World Demographics, Clinical Characteristics, and Treatment Patterns of Patients Treated with Emapalumab for Primary Hemophagocytic Lymphohistiocytosis in the United States: The Real-HLH Study

The Optimized HLH Inflammatory Index Is Associated with a Higher Stage of Lymphoma, but an Unexpected High Mortality Associated with Inflammation

Insights into the Natural History and Treatment Outcomes of Hemophagocytic Lymphohistiocytosis (HLH): The into-HLH Registry

Quercetin ameliorates XIAP deficiency–associated hyperinflammation

HLH: birds of a feather flock together

An improved index for diagnosis and mortality prediction in malignancy-associated hemophagocytic lymphohistiocytosis

Safety of Emapalumab in Pediatric Patients with Primary Hemophagocytic Lymphohistiocytosis (HLH): Relationship to Treatment Exposure

Real-World Treatment Patterns and Outcomes in Patients with Hemophagocytic Lymphohistiocytosis (HLH) and Other Clinical Conditions Treated with Emapalumab: The Real-HLH Study Design

Peri-Transplant Alemtuzumab Levels Predict Risk of Secondary Graft Failure and Inversely Impact CXCL9 Levels after RIC HCT (A Correlative Biology Study to BMT-CTN 1204 RICHI)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only